NCT07781345Not yet recruiting
A Postmarketing Study of LEQEMBI in United Kingdom (UK) Participants With Alzheimer's Disease (AD)
A Prospective Observational Registry Study to Evaluate the Use and Safety of LEQEMBI in Routine Clinical Practice
Source: ClinicalTrials.gov · Last updated 24 Aug 2026
Brief summary (registry, in English)
The primary purpose of the study is to describe the incidence and severity of known adverse events (AEs), including Amyloid-Related Imaging Abnormalities Oedema/Effusion (ARIA-E), Amyloid-Related Imaging Abnormalities-Microhemorrhage and Haemosiderin Deposit (ARIA-H), intracerebral hemorrhage greater than (\>) 1 centimeter (cm) in diameter, and anaphylaxis (stratified by apolipoprotein E4 variant \[APOE4\] genotype, concomitant antithrombotic therapy, and comorbid Cerebral Amyloid Angiopathy \[CAA\]), of LEQEMBI in routine clinical practice.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 400 (estimated)
- First submitted
- 31 Jul 2026
- Start date
- 31 Aug 2026
- Primary completion date
- 31 Dec 2031
- Lead sponsor
- Eisai Limited
- Diseases
- Alzheimer disease
- NCT number
- NCT07781345
What you commit to
- Study type: Observational
- Planned participants: 400
- From 31 Aug 2026 to the primary completion date, 31 Dec 2031
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- -Participation or planning to participate in randomised controlled trials (RCTs) for mild cognitive impairment (MCI) or AD, and patients who have had prior exposure to anti-amyloid monoclonal antibody (mAb) treatment including prior use of lecanemab.
Who the study is looking for
- The participant (and/or legally authorised representative) has provided written informed consent to participate in the Post-Authorisation Safety Study (PASS) and for use of their protected health information (PHI).
- The participant is registered in the Controlled Access Programme (CAP) and has been prescribed LEQEMBI.
Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Scottish Brain Sciences Coordinator of this site? Confirm its status | Edinburgh | United Kingdom | Unknown status |
| Recognition Health Limited Coordinator of this site? Confirm its status | London | United Kingdom | Unknown status |
| Neuroclnx Coordinator of this site? Confirm its status | Motherwell | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.